Gilder Gagnon Howe & CO LLC Vertex Pharmaceuticals Inc Transaction History
Gilder Gagnon Howe & CO LLC
- $7.87 Billion
- Q3 2024
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 2,040 shares of VRTX stock, worth $821,508. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,040
Previous 2,067
1.31%
Holding current value
$821,508
Previous $968,000
2.07%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,725Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.8 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.33 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.58 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.76 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.63 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $103B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...